[Comment] Rifampicin for Staphylococcus aureus bacteraemia: give it ARREST

Although Staphylococcus aureus bacteraemia is both common and potentially lethal, clinical decisions involving its treatment remain largely unencumbered by high-quality data.1 With the ARREST multicentre, randomised, double-blind, placebo-controlled trial, Guy Thwaites and colleagues2 have contributed high-quality evidence and addressed an unresolved question involving the role of adjunctive rifampicin in treatment regimens for patients with S aureus bacteraemia.
Source: LANCET - Category: General Medicine Authors: Tags: Comment Source Type: research